botensilimab + balstilimab

Botensilimab + balstilimab is an investigational combination immunotherapy regimen composed of two monoclonal antibodies developed by Agenus. Botensilimab is an Fc-enhanced anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) antibody designed to activate and expand immune responses against tumors, particularly in "cold" or poorly immunogenic solid tumors. Balstilimab is a programmed cell death protein 1 (PD-1) inhibitor that blocks the PD-1 pathway to enhance T-cell mediated antitumor activity. The combination aims to overcome resistance seen with single-agent checkpoint inhibitors in microsatellite stable (MSS) colorectal cancer and other solid tumors. Clinical trials have shown promising response rates and disease control in heavily pretreated patients with MSS metastatic colorectal cancer, as well as activity in refractory sarcomas[3][5][6][7][8][9][10].

Other names

BOT/BALBOT plus BALbotensilimab and balstilimab combination